/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Ensysce Biosciences Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.63 0.016(1.6%) ENSC at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 1.46
Highest Today 1.57
Today’s Open 1.57
Prev. Close 1.565
52 Week High 10.96
52 Week Low 1.47
Day’s Range: Low 1.46 High 1.57
52-Week Range: Low 1.47 High 10.96
1 day return -
1 Week return -11.29
1 month return -24.15
3 month return -25.94
6 month return -34.98
1 year return -79.14
3 year return -94.18
5 year return -
10 year return -

Institutional Holdings

Perceptive Advisors LLC 2.92

Adage Capital Partners Gp LLC 2.52

Geode Capital Management, LLC 0.34

Fidelity Extended Market Index 0.28

FNY Investment Advisers, LLC 0.10

Vanguard Institutional Extnd Mkt Idx Tr 0.08

SBI Securities Co Ltd 0.08

Spartan Extended Market Index Pool F 0.07

Fidelity Series Total Market Index 0.06

Tower Research Capital LLC 0.05

Spartan Total Market Index Pool G 0.03

Morgan Stanley - Brokerage Accounts 0.01

UBS Group AG 0.01

BlackRock Inc 0.00

Bank of America Corp 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

Murchinson Ltd. 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

Sabby Management LLC 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4.65 M

PB Ratio 5.2088

PE Ratio 0.0

Enterprise Value 4.98 M

Total Assets 5.60 M

Volume 49033

Company Financials

Annual Revenue FY23:0 0.0M, FY22:2523380 2.5M, FY21:3531200 3.5M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:-1368841 -1.4M, FY19:-3328674 -3.3M

Annual Net worth FY23:-12599980 -12.6M, FY22:-24961561 -25.0M, FY21:-29145750 -29.1M, FY20:-938726 -0.9M, FY19:1476354 1.5M

Quarterly Revenue Q3/2025:493104 0.5M, Q2/2025:1371438 1.4M, Q1/2025:1320000 1.3M, Q3/2024:0 0.0M, Q2/2024:181797 0.2M

Quarterly Profit Q3/2025:-2461805 -2.5M, Q2/2025:-551992 -0.6M, Q1/2025:1320000 1.3M, Q3/2024:null 0.0M, Q2/2024:-765432 -0.8M

Quarterly Net worth Q3/2025:-3729128 -3.7M, Q2/2025:-1733351 -1.7M, Q1/2025:-1946000 -1.9M, Q3/2024:661769 0.7M, Q2/2024:-1967793 -2.0M

Fund house & investment objective

Company Information Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Organisation Biotechnology

Employees 7

Industry Biotechnology

CEO Dr. D. Lynn Kirkpatrick Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow